ClinicalTrials.gg
Approved for marketingNCT04247906Updated Mar 5, 2026

Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab

An expanded access record providing Narsoplimab in Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA), sponsored by Omeros Corporation. Approved for marketing. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Omeros Corporation · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients
Sex
All
01

Study summary

The purpose of the EAP is to provide access to hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) patients who may benefit from treatment with narsoplimab based on the medical judgement of their respective physicians.

02

Conditions studied

  • Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)
03

In context

Thrombotic Microangiopathies

52 studies on the registry are indexed under Thrombotic Microangiopathies; 21 are open to participants now.

Browse Thrombotic Microangiopathies studies →

Lead sponsor

Omeros Corporation is the lead sponsor of 25 studies on the registry; 1 is open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All

Eligibility criteria

  • Patient (adult or pediatric) must have undergone or autologous hematopoietic stem cell transplant (HSCT)
  • Patient must be capable of understanding an form (ICF) or the parent or legal guardian of the patient is able to understand and sign a written ICF prior to the initiation of any treatment procedures.
  • Patient must have HSCT- TMA defined as having thrombocytopenia and evidence of microangiopathic hemolytic anemia.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

06

Where to request access

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT04247906
Lead sponsor
Omeros Corporation
Collaborators
Impatients N.V. trading as myTomorrows
Responsible party
Sponsor
First posted
Jan 30, 2020
Last update
Mar 5, 2026
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion